Literature DB >> 11100906

Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.

J Gabrielsson1, W J Jusko, L Alari.   

Abstract

The most common approach to in vivo pharmacokinetic and pharmacodynamic modeling involves sequential analysis of the plasma concentration versus time and then response versus time data, such that the plasma kinetic model provides an independent function, driving the dynamics. However, response versus time data, even in the absence of measured drug concentrations, inherently contain useful information about the turnover characteristics of response (turnover rate, half-life of response), the drug's biophase kinetics (F, half-life) as well as the pharmacodynamic characteristics (potency, intrinsic activity). Previous analyses have assumed linear kinetics, linear dynamics, no time lag between kinetics and dynamics (single-valued response), and time constant parameters. However, this report demonstrates that the drug effect can be indirect (antinociception, cortisol/adrenocorticotropin (ACTH), body temperature), display nonlinear kinetics, display feedback mechanisms (nonstationarity, cortiso/ACTH) and exhibit hysteresis with the drug levels in the biophase (antinociception, body temperature). It is also demonstrated that crucial determinants of the success of modeling dose-response-time data are the dose selection, multiple dosing, and to some extent different input rates and routes. This report exemplifies the possibility of assigning kinetic forcing functions in pharmacodynamic modeling in both preclinical and clinical studies for the purpose of characterizing (discrimination between turnover and drug-specific parameters) response data and optimizing subsequent clinical protocols, and for identification of inter-individual differences.

Entities:  

Mesh:

Year:  2000        PMID: 11100906     DOI: 10.1002/1099-081x(200003)21:2<41::aid-bdd217>3.0.co;2-d

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  20 in total

1.  Use of pharmacokinetic data below lower limit of quantitation values.

Authors:  William J Jusko
Journal:  Pharm Res       Date:  2012-06-23       Impact factor: 4.200

2.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

Review 3.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients.

Authors:  Amelia Ramon-Lopez; Ricardo Nalda-Molina; Belen Valenzuela; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2009-06-02       Impact factor: 4.200

5.  A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling.

Authors:  Erno van Schaick; Jenny Zheng; Juan Jose Perez Ruixo; Ronald Gieschke; Philippe Jacqmin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-06-30       Impact factor: 2.745

6.  Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Authors:  Mario González-Sales; Fahima Nekka; Mario Tanguay; Pierre-Olivier Tremblay; Jun Li
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

Review 7.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

8.  Kinetic-pharmacodynamic model for drugs with non-linear elimination: Parameterisation matters.

Authors:  Qing Xi Ooi; Chihiro Hasegawa; Stephen B Duffull; Daniel F B Wright
Journal:  Br J Clin Pharmacol       Date:  2020-01-10       Impact factor: 4.335

9.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

Authors:  Goonaseelan Pillai; Ronald Gieschke; Timothy Goggin; Philippe Jacqmin; Ralph C Schimmer; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

10.  Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice.

Authors:  Yvonne Y Lau; Peiming Ma; Leonid Gibiansky; Renee Komorowski; Jin Wang; George Wang; Hai Yan; Murielle M Véniant; Tarundeep Kakkar
Journal:  AAPS J       Date:  2009-10-23       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.